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Case presentation
A 30-year-old woman with a long history of polyuria, urinary
frequency, urinary tract infection, and intravenous heroin abuse was
admitted to the New England Medical Center for initiation of continu-
ous ambulatory peritoneal dialysis (CAPD). Two years before admis-
sion, she presented to another hospital because of malaise. An intrave-
nous pyelogram at that time revealed bilaterally small kidneys with
dilated ureters; the serum creatinine was 7.0 mg/dl. Hemodialysis,
begun 1.5 years ago because of total renal failure, was tolerated poorly.
Shortly after admission, a Tenckhoff catheter was inserted and the
patient was instructed in the technique of CAPD. Three weeks later,
CAPD was begun using four exchanges daily. The patient did well for
approximately 10 weeks but then developed nausea, vomiting, and
.mitlepigastric pain. Twelve hours later she had more generalized
abdominal pain, fever, chills, and two episodes of watery diarrhea.
After noticing that the dialysate was cloudy, she came to the emergency
room for evaluation. Her medications at that time included 2 tablets of
dihydrotachysterol daily and 4 to 6 capsules of Basaijel three times
daily. Her diet contained 80 g of protein and was moderately low in salt.
Physical examination revealed a well-nourished white female with
moderate abdominal distress. The temperature was 38.5°C; blood
pressure, 110/64 mm Hg; pulse, 100 per minute and regular; and
respirations, 18 per minute and regular. Abdominal examination
showed guarding, greatest over the epigastrium, with pain radiating to
the left lower quadrant. There was no rebound tenderness. No erythe-
ma, fluctuance, induration, or tenderness was apparent along the
catheter tract. Bowel sounds were diminished. Pelvic and rectal exami-
nations were unremarkable.
Laboratory data included a white blood cell count of 9700/mm3 with
60 polymorphonuclear cells, 23 bands, 11 lymphocytes, and 5 mono-
cytes. The hematocrit was 19%; serum sodium, 138 mEq/liter; potassi-
um, 4.3 mEq/liter; bicarbonate, 21 mEq/liter; chloride, 101 rnEq/liter;
BUN, 90 mg/dl; and serum creatinine, 14.4 mg/dl. The peritoneal
dialysis fluid contained 64 white blood cells/mm3 with 93% polymorpho-
nuclear cells, 2% monocytes, and 5% eosinophils. Gram stain of the
peritoneal dialysis fluid revealed gram-positive cocci. An abdominal
plain film revealed a pattern consistent with ileus. Culture of the
peritoneal dialysis fluid showed Staphylococcus aureus. Peritonitis was
diagnosed, and the patient was treated with cefazolin sodium intrave-
nously for 2 days and then orally for 8 days. Cefazolin also was added to
each dialysis bag. The patient performed exchanges every 2 hours for
the first 12 hours, and then every 4 hours for the next 24 hours. Fever
disappeared the morning after admission, and abdominal pain, nausea,
and vomiting abated over the next 6 days. Abdominal examination
became unremarkable, ileus resolved, and the patient was discharged 6
days later.
She did well until 2 weeks later when, awakened from sleep by
abdominal pain, she noted that the dialysate again was cloudy. She
experienced nausea and one episode of vomiting but denied diarrhea,
fever, or chills. The dialysate the night before, when she had done her
last exchange, had been clear. She had not noticed any change in
technique or leak in the system. According to protocol, she added 1500
mg of cefazolin to each 2 liters of dialysate and also began taking the
drug orally. She then went to the emergency room, where her tempera-
ture was 37°C and blood pressure was 180/80 mm Hg. She did not
appear toxic. Abdominal examination revealed no evidence of infection
along the catheter tract. There was mild diffuse abdominal tenderness
without rebound, and some slight voluntary guarding. Bowel sounds
were sluggish. Laboratory data revealed a white blood cell count of
10,900/mm3 with 85% polymorphonuclear cells, 5% bands, 6% lympho-
cytes, and 4% mononuclear cells. The hematocrit was 28%; BUN, 80
mg/dl; and serum creatinine, 11.9 mg/dl. Gram stain of the dialysate
revealed many polymorphonuclear leukocytes but no organisms. The
patient was treated with intraperitoneal and oral cefazolin sodium and
cefaclor for 14 days. Although the initial diatysate cultured S. aureus,
cultures taken after 2 days of treatment were sterile.
The patient was retrained in dialysis procedures, and she performed
several exchanges under supervision of a CAPD nurse specialist, who
found no flaw in her technique. The patient did well until 3 weeks later,
when she again presented with cloudy dialysate and abdominal discom-
fort. The dialysate again grew S. aureus with the same sensitivities as
previously. There was no evidence of catheter tract infection. She was
treated with intravenous and intraperitoneal antibiotics, and the CAPD
catheter was removed. She returned to hemodialysis with the under-
standing that she would be reconsidered for CAPD in 6 months.
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Table 1. Organisms from patients with peritonitis
Discussion
DR. STEPHEN I. VAS (Professor of Medical Microbiology and
Medicine, University of Toronto, and Microbiologist in Chief,
Toronto Western Hospital, Toronto, Canada): This patient
shows many of the features characteristic of Staphylococcus
aureus peritonitis in patients treated with CAPD. Aftcr two and
one-half months of CAPD, the patient came to the hospital with
abdominal pain and cloudy dialysate. Gram stain of the fluid
revealed gram-positive cocci, although the peritoncal dialysate
had only 64 white blood cells/mm3 with a predominance of
polymorphonuclear cells. Culture of the fluid grew S. aureus;
the patient was treated with antibiotics and had an uneventful
recovery.
Gram stain of the peritoneal fluid is a useful test in patients
with signs of peritonitis. In our experience, gram stain shows
microorganisms in about one-half of these patients. This patient
is unusual in that she had a relatively low white cell count in the
peritoneal fluid; even without peritonitis, there usually are
approximately 50 white blood cells/mm3, mainly mononuclear,
in the dialysate. The peritoneal fluid usually becomes cloudy
when it contains approximately 200 to 300 white blood cells/
mm3. In this patient, therefore, cloudiness might have been due
to fibrin secondary to the inflammation.
The patient's second episode of peritonitis occurred soon
after the first; this episode was remarkable because the perito-
neal fluid became cloudy rapidly. We have observed one patient
who initially had a clear dialysate, but one hour later, when the
patient complained of abdominal pain, cloudy fluid containing
numerous white cells was drained. A culture of the initial clear
fluid had been obtained serendipitously, and the cultures of
both the clear and the cloudy fluid were positive. The acute
cellular inflammatory response thus can develop very rapidly;
the rapidity of the influx of white blood cells into the peritoneal
cavity signifies a strong chemotactic stimulus. We have yet to
discover what is happening in the peritoneum between the
initiation of infection and the subsequent signs and symptoms of
inflammation.
Fortunately, S. aureus peritonitis, seen on three occasions in
this patient, is a relatively unusual complication. In our patient
population, S. aureus causes only about 15% of episodes of
peritonitis. Unfortunately, however, this type of peritonitis
often recurs, either because the infection is initiated by an
infected exit site or catheter tract infection, or possibly because
the organism causes abscesses in the peritoneal cavity that are
impervious to antibiotics. When mice are injected intraperitone-
ally with S. aureus, a "clumping factor" triggers fibrin produc-
tion around the organisms and produces clusters. These clus-
ters shield organisms from phagocytosis, and antibiotic diffu-
sion into these fibrin clots may be diminished. I will consider
the possible benefits of rifampin on staphyloccal infections later
11—31.
This patient manifested fever, chills, and two episodes of
watery diarrhea during her first episode of peritonitis. Recently
staphylococcal infections associated with tampon use have
been described as the toxic shock syndrome [41. Although most
of the patients described are women, a similar syndrome occurs
in males, and even in women it is not always associated with
tampon use 115, 61. It is not clear whether the toxic shock
syndrome is associated with only certain staphylococci that
produce a specific toxin. It is possible that patients on peritone-
al dialysis who are infected with the putative causative orga-
nism of toxic shock syndrome might develop the full-blown
Organism
No. of episodes
J977,
Number of organisms isolated
1978 1979 1980 1981 Total
52 53 28 33 169
Percentage of
total
organisms
isolated
S. epidermidis 1 24 25 17 9 76 38.2
S. aureus I It) 5 2 II 29 14.6
S. viridans I 6 6 7 4 24 12.1
Lnterococcus 2 4 6 3.0
Streptococcus species 3 1 4 2.0
F. co/i 3 4 I 2 10 5.0
Klebsiellu/Lnterobacter 4 2 1 7 3.5
Proteus species 3 I 4 2.0
Citrobacter 2 2 1.0
Pseudornonas species 6 1 I 8 4.0
Acinetobacier 3 1 I 5 2.5
Flavohacterium I I t).5
Bacteroides species 1 3 2 6 3.0
Fusohacterium I I 0.5
Clostridium species 1 1 2 I tI
Propionibacteriurn 1 1 2 1.0
Yeast/fungus 5 1 I 7 3.5
Other
Total number of
1 2 I 1 5 2.5
organisms isolated
Refers to two months only
3 65 19963 32 36
Microbiologic aspects of CA PD 85
syndrome of toxic shock. For this reason it is prudent to
hospitalize patients with peritonitis who have fever, diarrhea.
or skin erythema. Therapy for toxic shock syndrome is the
same as that for staphylococcal peritonitis, namely, aggressive
intravenous antibiotic therapy and other supportive measures
as needed.
Peritonitis in CAPD patients
Let me turn from a discussion of this patient to a broader
analysis of the problem of peritonitis in patients on CAPD.
Peritoneal lavage has been used since the mid—l940s to remove
waste products in patients with end-stage renal disease [71, but
its widespread use was hindered until the risk of peritonitis was
reduced to acceptable levels. After Tenckhoff improved access
to the peritoneal cavity by introducing his now-famous catheter
[8], peritoneal dialysis became an acceptable process. Although
peritonitis lessened in frequency, it still limited the use of
peritoneal dialysis, as did other factors: at that time, peritoncal
dialysis was machine oriented, could be used only in dialysis
centers, required a large time commitment from the patient, and
necessitated the building of costly peritoneal dialysis units.
In 1976, Popovich and colleagues described a new method of
peritoneal dialysis: they used bottled dialysate and four ex-
changes per day, thus making the method affordable and
suitable for home programs [9]. Oreopoulos and colleagues
modified the technique by using plastic bags for dialysis fluid,
thereby reducing considerably the number of connections be-
tween dialysate bag and peritoneal catheter and making the
method feasible for home dialysis in large numbers of patients
[10]. But peritonitis was still a frequent event [11—14]. It was
clear that new methods were required for reducing the infection
rate. Moreover, it seemed likely that treatment for this compli-
cation would require new directions because the management
of this infection was based entirely on experience gained from
treating postoperative peritonitis [15—17].
Diagnosis of peritonitis
For clinical and microbiologic research purposes, we diag-
nose peritonitis if any two of the following three criteria are
present: (1) abdominal pain or tenderness; (2) cloudy peritoneal
fluid containing greater than 100 neutrophils/mm3; and (3)
microorganisms in the peritoneal fluid. A review of patients
admitted to our hospital for peritonitis defined according to
these criteria showed that approximately 80% had abdominal
signs and symptoms, whereas fever was present only in 23%
[14, 18]. The peripheral white blood cell count was not reliably
elevated and did not have prognostic or diagnostic value.
Microorganisms isolated from our CAPD patients with peri-
tonitis are summarized in Table 1. Approximately two-thirds of
the organisms were gram positive; about 20% were gram
negative. Anaerobic organisms, fungi, and some rare microbio-
logic agents make up the rest.
Initial studies on the cause of peritonitis in patients undergo-
ing dialysis reported a high incidence of aseptic peritonitis [12,
131; this observation implied that no microbial cause existed for
these infections. We doubt that 'sterile" peritonitis is so
frequent. We believe that in patients undergoing CAPD, the
presence of 2 to 3 liters of dialysis fluid in the peritoneal cavity
simply dilutes the organisms and that when conventional meth-
ods are used for diagnosis, organisms often escape detection
because of their low number. To avoid this error, we use
'concentrated" dialysate to increase the likelihood of our
making a specific microbiologic diagnosis [13, 19, 20]. We use a
filtration method originally devised for testing the sterility of
pharmaceutical products (Addicheck; Millipore Corporation,
Bedford, Massachusetts). First, 100 ml of peritoneal fluid is run
through the filter (with a "pore size" of 0.45 microns) and the
filter is washed twice with sterile saline. We then fill the
container holding the filter with culture medium and incubate it,
We use thioglycolate medium, which supports most of the
fastidious organisms expected in peritonitis, including anaer-
obes. If the peritoneal fluid contains large numbers of cells or
fibrin, this technique is not suitable. Instead we centrifuge
100 ml of peritoneal fluid and culture the washed sediment. The
washing procedure possibly removes antibiotics present in the
peritoneal fluid that inhibit bacterial growth.
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Fig. 1. Effects of pH on activity ofpolvrnorphonuclear blood cells. Cells
were incubated in phosphate-buffered, balanced salt solution at the
indicated pH and were assayed for chemiluminescence (A), phagocyto-
sis (B), and bactericidal activity (C). Each point is the mean SD of 3
to 6 determinations (from Ref. 26).
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Fig. 2. Effect of osmolality on actil'itv of polymorphonuclear blood
cells. The osmolality of a basal Dianeal solution was increased by the
addition of dextrose and the cells were assayed for chemiluminescence
(A), phagocytosis (B), and bactericidal activity (C) (from Ref. 26).
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Fig. 3. Effect otpolymorjhonucleor blood cell concentration out/fluid
volume on bacterial killing. Volumes (opcn circles) or ccli concentra-
tion (closed circlet) was varied. Bacteria/cell ratio was kept 1:1 in all
tests (from Ref. 261.
These methods increase the yield of positive cultures over
that obtained with conventional techniques. With these tech-
niques, we rarely if ever fail to obtain a positive culture in a
patient with pain and cloudy dialysate. An added benefit of
culturing a large volume of dialysate is the decreased time
necessary to detect bacterial growth. Earlier diagnosis and
institution of antibiotic treatment therefore are made possible.
When we were certain that our methods for detecting micro-
organisms in dialysate from patients with peritonitis had suffi-
cient sensitivity, we addressed ourselves to the difference
between peritonitis complicating CAPD and postoperative peri-
tonitis F21l. Bacterial contamination of the peritoneum leads to
surgical peritonitis in only a small fraction of instances. In fact,
during almost all abdominal procedures small numbers of
microorganisms are introduced from the air. Postoperative
infection of all types occurs in only 3% to 5% of patients;
peritonitis probably accounts for only a small fraction of these
infections, although the true incidence is not known. Indeed.
clinical peritonitis usually develops only after fecal material
grossly contaminates the peritoneal cavity.
In contrast to stargical peritonitis, peritonitis in CAPD occurs
frequently despite apparent minimal contamination, but per-
haps as a consequence of a greater number of minor episodes of
contamination. In addition, we rarely observe positive blood
cultures in patients on CAPD who develop peritonitis, whereas
approximately 30% of patients with surgical peritonitis have
bacteremia. 1 will refer to the exceptions to these observations
Host defnse mechanisms
The defense mechanisms of the peritoneal cavity are numer-
ous but are not well understood. We know that immunoglobulin
and complement are present in the peritoneal fluid, that phago-
cytic mechanisms are operational, that various enzymes are
present, and that fibrinolytic activity is necessary for proper
function of the normal peritoneum. Indeed, a decrease in
fibrinolysis results in fibrin formation and adhesions. Such
adhesions are, of course, an early complication of peritonitis
[22]. In the normal peritoneal cavity, bacterial invasion rapidly
changes the usual mononuclear cell population to a polymor-
phonuclear cell population. The rapid inflammatory response is
a function of chemotactic stimuli. Bactericidal action is rapid
and can clear the peritoneum without antibiotic agents. Patients
in renal failure have a heightened susceptibility to infection,
however, secondary to both cellular immune suppression and
decreased reticuloendothelial t'unction [23—29]. I now would
like to turn to a discussion of changes in the peritoneal defense
mechanisms in patients undergoing CAPD.
The peritoneal cavity of those patients contains, instead of
the normal few milliliters of fluid, 2 liters of dialysis fluid.
Further, the pH of normal peritoneal fluid is 7.4 and is isoosmo-
lar, whereas dialysate has a low pH (5.5) and a high osmolality
because an osmotic agent (usually glucose) is added to produce
high rates of ultrafiltration. After entering the peritoneal cavity,
dialysate equilibrates with blood, and the pH of the fluid
increases toward that of the blood over 20 to 45 minutes. The
decrease in osmolality is slower, usually taking about 3 hours.
During the initial interval, the peritoneal phagocytic cells oper-
ate under nonphysiologic conditions; we found that both the
low pH and the hyperosmolality severely depress phagocytic
activity and bactericidal ability of peritoneal cells (Figs. I and 2)
[30, 31]. These observations lead us to believe that the phago-
cytic efficiency of peritoncal fluid in patients on CAPD is
diminished, at least in the initial period of each exchange.
in addition to the pH and osmolar changes, urea, creatinine,
and other low-molecular-weight substances diffuse into the
peritoneal fluid. We have not found, however, any serious
depressing effect of urea on phagocytosis at a concentration of
100 mg/dl. Similarly, heparin. which occasionally must be
administered to prevent fibrin formation [321, did not affect
phagocytosis or bactericidal action in a concentration of 500 UI
liter.
Finally, we have investigated the importance of the cell-to-
bacterium ratio in infected peritoneal fluid. Because bacterial
elimination requires that the phagocyte has membrane-to-mem-
brane contact with the bacterium, we assume the fluid volume
in which this encounter takes place is important. By maintain-
ing the volume of fluid, we altered the ratio of bacterium-to-cell
per unit volume. We also have studied the effect of increasing
the fluid volume while maintaining the same cell-to-bacterium
ratio. Our experiments demonstrate that the efficiency of
phagocytosis and killing decreases rapidly if the volume in-
creases or if the phagocytic cell concentration decreases (Fig.
3). 1 will discuss how we have modified our approach to therapy
as a consequence of these findings.
Treatment of peritonitis
With these principles in mind, let us consider the charaeteris-
100
0)c
St
0
later. ties and treatment of peritonitis in patients being managed with
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Table 2. Peritonitis in patients on CAPD
Percentage
Organism of cases Response to treatment Remarks
Staphylococcus 40 Mild presentation; responds well Home management appropriate
epidermidis
Staphylococcus 10 Severe presentation; may require combination Tends to form abscesses; may require catheter
aureus therapy with rifampin removal; tunnel infection frequent
Streptococcus 10 Severe presentation; good response to antibiotics Origin probably hematogenous from oropharyngeal
viridans group source
Gram-negative 20 Severe presentation; good response to antibiotics If more than one species cultured, possible
enteric organisms intestinal perforation
Anaerobic 1—5 Severe presentation Indicates intestinal leak; may require laparotomy
organisms
Fungi 5—6 Severe presentation; does not respond to
antifungal agents
Requires catheter removal
M. tuberculosis 1—2 Insidious presentation; mononuclear cells in fluid Requires catheter removal and prolonged anti-TB
chemotherapy
CAPD (Table 2). The most frequent portal of entry for these
infections is the catheter or tunnel through which the catheter
enters the peritoneal cavity. Less often, organisms enter the
peritoneal cavity from endogenous sources, such as the bowel,
in which case severe peritonitis results. In fact, preexisting
diverticulosis increases the risk that a patient treated with
peritoneal dialysis will develop peritonitis. We also assume that
S. viridans peritonitis is a consequence of endogenous infec-
tion, with bacteremia preceding the peritonitis. Indeed, we have
documented bacteremia in a few patients who developed perito-
nitis with S. viridans.
Aseptic peritonitis has been reported [33] and anecdotal
reports are common, but, as 1 discussed earlier, so-called
aseptic or culture-negative peritonitis usually is due to inade-
quate laboratory technique. Most large peritoneal dialysis units
that currently use sophisticated laboratory techniques have
noted a decrease or absence of so-called culture-negative
peritonitis. Sometimes cloudy peritoneal fluid is seen in the
absence of bacteria, but these patients usually have no abdomi-
nal symptoms or signs, and no treatment is needed. Further
studies are required to explain the phenomenon of eosinophilic
peritonitis, which occurs soon after catheter implantation and
which probably arises because of chemical irritation.
As noted earlier, therapy for peritonitis in patients on CAPD
initially was fashioned after treatment of surgical peritonitis.
The peritoneal cavity was lavaged with large volumes of
peritoneal fluid containing antibiotics. Therapeutic results were
adequate, but we were dissatisfied with this approach because
the large volume of dialysate flowing through the peritoneal
cavity (60 to 120 liters per day) removed phagocytic cells and
did not give the peritoneum an opportunity to clear offending
organisms itself. In addition, the dialysate remains acidic and
hyperosmolar when the flow of dialysate is so large. To avoid
this unfavorable milieu, we substituted the following regimen
for large-volume peritoneal lavage. We perform three rapid in-
and-out exchanges with dialysate containing no antibiotics to
remove inflammatory products and to provide symptomatic
relief. We then reduce the volume of fluid administered to 1 liter
and increase the dwell time to 3 hours; antibiotics and heparin
also are added until the patient improves. When improvement
does occur or when the dialysate becomes sterile, the patient's
previous dialysis schedule is reinstituted and antibiotics are
added to the dialysis fluid. This regimen is continued for 7days
after we obtain a negative peritoneal fluid culture. As Table 3
illustrates, the fluid becomes bacteriologically negative within 3
days in approximately two-thirds of patients; the total length of
antibiotic treatment therefore is usually 10 days. If the patient is
in satisfactory clinical condition and is able to add antibiotics to
the dialysate bag, or if oral antibiotics can be used, we
discharge the patient and complete the treatment at home.
Table 4 compares our results in 1978 and 1979, when large-
volume lavage was the main therapeutic approach, to results in
1980 and 1981, when most patients were treated with the
method I just outlined. Although the latter group contained
more diabetic and, hence, high-risk patients, the average length
of treatment and hospital stay in this group was substantially
lower; these results support the appropriateness of our treat-
ment regimen [14, 18, 33—361.
Selection of antibiotics requires some discussion. Most orga-
nisms isolated from patients on CAPD who develop peritonitis
are sensitive to either cephalothin or tobramycin. We use
cephalothin because its limited protein binding allows it to
diffuse into the peritoneal cavity and penetrate into cells. We
use tobramycin in preference to other aminoglycosides because
it produces fewer side effects [37, 381. Several other antibiotics
also can be used for treatment of peritonitis, including vanco-
mycin, cloxacillin, and ticarcillin. Initially, we give a loading
dose that will achieve proper serum as well as peritoneal fluid
concentrations (Table 5). We aim to achieve 4 to 5 times the
minimal inhibitory concentration needed for the suspected
organism. Thereafter we try to maintain a steady state, estimat-
ing input and removal through dialysis only, although some of
these patients have some residual renal function. Measurement
of antibiotic concentrations in serum and in peritoneal fluid
from patients treated in this fashion discloses therapeutic levels
of the drugs [37]. When using nondiffusible antibiotics such as
vancomycin, we give the antibiotic intraperitoneally as well as
intravenously. Otherwise, we do not use any parenteral antibi-
otics. Before a definite bacteriologic diagnosis is established,
we use cephalothin and tobramycin, because these agents
inhibit most of the organisms encountered. The antibiotics are
changed if microbiologic identification and antibiotic sensitivity
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data warrant. Patients usually improve symptomatically within
24 to 36 hours, and the number of inflammatory cells in the
peritoneal fluid decreases [39]. Despite a relatively high concen-
tration of antibiotics in the dialysate, especially tobramycin, we
have not observed any side effects due to antibiotics.
We recently have started using rifampin to treat peritonitis
associated with infections at the catheter exit site and in the
catheter tunnel, especially if the causative organism is
S. aureus. Rifampin has good antistaphylococcal activity and
excellent penetration even into phagocytic cells. The possible
emergence of organisms resistant to rifampin, however, re-
quires that this agent be used in combination with other
antibiotics. Although we have no controlled studies proving the
efficacy of rifampin, we have an impression that it is a useful
agent in the treatment of peritonitis due to S. aureus and
occasionally S. epiderruidis [I, 2].
Peritonitis due to /t"Iycohocteriurn tuberculosis is a rare
complication, requiring antituberculous chemotherapy and re-
moval of the catheter [40, 41]. Our experience with fungal
peritonitis suggests that chemotherapy can temporarily mitigate
symptoms, but ultimately antifungal therapy is unsuccessful,
and the catheter has to be removed [42]. There are other rare
infectious causes of peritonitis in patients on CAPD that
represent a diagnostic and therapeutic challenge [43], but I will
not discuss these occurrences here. In a randomized controlled
study, antibiotic prophylaxis—an attractive theoretical solution
to the problem of recurrent peritonitis—did not prove effica-
cious [44—48].
Infected catheter exit sites and access tunnels often cause
peritonitis. Clear guidelines for catheter removal have been
established. All avenues of treatment must be examined before
a decision is made to remove the catheter, l'ahle 6, which
summarizes our pragmatic approach to this problem, lists our
indications for catheter removal.
The future of CAPD as a long-term therapeutic modality
depends on the incidence of peritonitis. The best way to
measure the incidence of peritonitis is still hotly debated. The
number of episodes of peritonitis per patient years, months, or
days ignores the problem of nonconcurrent controls and the
importance of previous episodes of peritonitis in the patients
selected for study. Therefore a more sophisticated statistical
approach is needed for evaluation of peritonitis in patients
treated with peritoneal dialysis [49—5 1]. In our unit we estimate
the rate of peritonitis by performing life-table analysis 52].
Figure 4 shows the peritonitis rate in our unit between 1978 and
1981. The differences are not statistically significant, but a trend
toward a lower rate has emerged recently. Figure 5 illustrates
the effect of technical innovations, namely, the introduction of
the titanium connector (Travenol Laboratories) and the per-
formance of tubing changes by nurses. By using this statistical
method, we measure the incidence of peritonitis in patients
before and after these innovations and use these patients as
their own controls.
We also have compared the incidence of peritonitis in diabet-
ic and nondiabetie patients (Fig. 6) using this analytic method.
In our unit we treat many diabetic patients with peritoneal
dialysis with good results [53]. Originally we were concerned
that these patients would he prone to infection, especially
because insulin was being instilled into their dialysis bags,
providing yet another portal of entry. Fortunately, this concern
proved groundless; peritonitis rates were equal to or lower than
those of our nondiabetie patients.
I would like to note in passing that we recently reviewed the
transplant results in our CAPD patients. Infections were not a
major problem in these patients [54].
Many questions regarding peritonitis in patients on peritoneal
dialysis remain unanswered. Further studies are required to
explain why certain contaminations lead to peritonitis and
others do not. Future technical innovations probably will
reduce the rate of peritonitis even further. At present, however,
proper diagnostic and therapeutic approaches allow us to keep
peritonitis from being a life-threatening complication in the
burgeoning number of patients being treated with peritoneal
dialysis.
Questions and answers
DR. DAVID SNYDMAN (btfectious Disease Division, NEM('):
Dr. Vas, is it possible that skin bacteria travel up a fibrous
sheath alongside the catheter, much as bacteria travel around
indwelling Foley catheters, rather than gain access during
"connection" episodes?
DR. VA5: I suspect that there are several portals of entry.
Overall, the organisms that cause peritonitis can come from the
skin, intestines, or blood. One has to accept that if the patient
accidentally touches the spike before piercing the bag, or if a
major departure from technique occurs, contamination can
result. Other infections probably do track down along the
Duration
days
Table 3. Duration of positive cultures in peritonitis in patients on
CAPD
Table 4. Treatment for peritonitis in patients on CAPD
1978—1979 198t)—1981
1977 1978 1979 1980 1981 Percentage Episodes of peritonitis 114
___________________________- Patients
28 19 tO 8 37.3 Mean age/year 47
16 8 10 5 22.t) Diabetics 9
3 6 2 I 6.8 Treatment
6 4 1 3 7.9 Lavage
I 3 2 2 4.5 CAPI)
1 2 2.3 Days of treatment/pt
I I I 1.7 Days in hospital/pt
3 7 1 5 lOt) —- ----——-- _______________ -
3 4 4.1 °< 0.03
_________ "P< 0.01
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catheter tunnel. Different groups use single- or double-cuff
catheters; in my mind the major site of the problem is the cuff
area. Bacteria can track down through the tunnel surrounding
the catheter because the skin never totally closes against the
catheter. There is probably a firm attachment at the rectus
sheath, but we don't know how resistant this tissue is to
infection. We only suspect it when the catheter is removed
because of infection, so we have little or no information
regarding the tunnel in patients who are doing well. The
subcutaneous cuff is a major problem because it can work its
way out. In the sizable number of patients with "catheter
extrusion," the cuff moves outside the skin and becomes a
nidus for infection. In some patients who have thick abdominal
walls, the tubing retracts and acts like a piston as it is tugged
during bag changes. This motion might pump bacteria down the
tunnel. Thus, 1 think many of the infections come from the skin
through the exit site or through the tunnel.
DR. SNYDMAN: We have been interested in quantitative
cultures of arterial catheters after rolling the catheter along the
blood plate. Are there any such studies of catheters in patients
treated with CAPD?
DR. VAS: We look at every catheter that has to be removed.
We have reported one patient in whom certain fungi (Fusarium
species, a plant pathogen) grew in the Silastic catheter. With
bacterial infections, we haven't found colonies growing on the
catheter; the catheters are clean and shiny without much fibrin
on them.
DR. MICHAEL MADAIO (Renal Service, NEMC): What is the
incidence of tunnel infections in patients in whom the catheter
is removed because they have had more than three infections?
DR. VA5: It is difficult to answer your question because the
tunnel is not routinely explored during removal if there is no
evidence of prior tunnel infection. Certainly there are many
cases of recurrent peritonitis not associated with tunnel infec-
tion. On the other hand, tunnel infections in some patients can
be managed for months or sometimes years, and these infec-
tions don't necessarily lead to peritonitis. But the patient is
continuously threatened by the possibility of peritonitis. We do
not treat tunnel infections with systemic or local antibiotics; we
simply wash the affected area with hydrogen peroxide and
Betadine.
As far as local care of the exit site is concerned, one-half of
our patients have no bandages on the exit site, and they shower
every day. We permit patients to swim in their own private
swimming pools but not in public pools. Whether this is the
right or wrong approach I don't know. I am convinced that
some other factor is involved in the pathogenesis of peritonitis
in CAPD patients that we have not identified yet. It would be
important for us to know why one potentially infectious event
leads to peritonitis and other events do not.
DR. J. MICHAEL LAZARUS (Renal Division, Brigham and
Women's Hospital, Boston): In your study comparing large-
volume lavage and your newer technique. was lavage used in
conjunction with intravenous antibiotics?
DR. VAS: No, lavage was used with intraperitoneal antibiotics
only.
DR. LAZARUS: Have you studied the duration of hospitaliza-
tion and the success rates in patients treated with intraperitone-
al or intravenous anlibiotics?
DR. VAS: No, we haven't. We initially looked at intraperito-
neal versus intravenous antibiotics and the "travel time" to and
from the peritoneurn and the blood stream. We found that
intraperitoneal antibiotics equilibrate with the blood in about 3
hours. The reason we don't treat patients with peritonitis
intravenously is that we have easy access to the peritoneum
with the catheter.
DR. LAZARUS: If you could reduce the patient's hospital stay
by one-half, would it not be worthwhile giving intravenous
antibiotics?
DR. VAS: I don't think so, because we deliver the same
amount of antibiotics intraperitoneally as we would deliver
intravenously. Only he initial few hours are different. Usually I
am asked whether I am concerned that intraperitoneal antibiot-
ics do not suffuse the blood stream fast enough for systemic
treatment. If these patients were bacteremic I would be con-
cerned and would give them intravenous antibiotics. Because
they are not bacteremic, I do not worry that equilibration with
the blood takes 3 hours. The only time we give intravenous
antibiotics is when we have to use vancomycin, an antibiotic
that does not pass through the peritoneal membrane easily.
DR. ANDREW LEVEY (Renal Service, NEMC): How do you
manage the peritoneal catheter after kidney transplantation in
patients treated with CAPD? Have you found episodes of
peritonitis after transplantation?
DR. VAs: We leave the peritoneal catheter in for about 3
months after transplantation. The catheter is rinsed with small
Table 5. Antibiotic dosage for patients on CAPD Table 6. Indications for removal of a peritoneal catheter
Antibiotic Loading dose Maintenance dose Infectiou. causes
Persistent skin exit site or tunnel infection
l'obramycin
Cephalothin
Ampicillin
Cloxacillin
Penicillin
Ticarcillin
SMZ' + IMP5
Clindamycin
1.7 mg/kg 13W/bag
500 mg/liter
500 mg/liter
1000 mg/liter
I million U/liter
1000 mg/liter
SMZ, 400 mg/liter
{TMP, 80 mg/liter
300 mg/liter
8 mg/liter
250 mg/liter
50 mg/liter
100 mg/liter
50,000 U/liter
100 mg/liter
{SMZ.
25 mg/liter
T P, 5 mg/liter
50 mg/liter
Recurrent peritonitis with the same organism
Intraperitoneal abscess
Fungal peritonitis
Tuberculous peritonitis
Fecal peritonitis
Peritonitis not responding to adequate therapy for 5 to 7 days
Mechanical causes
Persistent leaks
Amikacin
Vancomycin
Amphotericin B
5-Fluorocytosin
125 mg/liter
1000 mg/liter
25 mg/liter
30 mg/liter
5 mg/liter
100 mg/liter
One way (outflow) obstruction
Permanent obstruction
SMZ refers to sulfamethoxazole.
TMP refers to trimethoprim.
Of questionable value.
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volumes of saline or Ringer's solution containing heparin once
or twice weekly and is capped. We have rcviewed our results in
such patients recently [501. We have had some episodes of
peritonitis, but they were not unusual types. Infections are most
frequently associated with ncglect of the catheter.
DR. MARTIN GELMAN (Renal I)ivision, St. Elizabeth's Hospi-
tal, Boston): Have you seen any patients with abscess forma-
tion? How do you diagnose an abscess?
DR. VA5: Yes, we have. In fact, we have seen an abscess that
was first noted several years after the initial episode of peritoni-
tis. Occasionally we have found gram-negative bacilli or anaer-
obic organisms (Bacteroides species) in unsuspected abscesses.
We suspect that earlier episodes of diverticulitis produced
abscesses that managed to seal off. The diagnosis of an abscess
in the peritoneal dialysis patient is difficult. The clinical course
and signs are the most useful in assessing the patient. Abscess
becomes an increasingly likely diagnosis if the pain becomes
localized, if the therapeutic response is slow, if the peritoneal
fluid white blood cell count does not decrease, or if it suddenly
increases. The CT scan is probably the most useful diagnostic
Time, months
Fig. 6. Risk of peritonitis in diabetic (closed circles, N = /70) and
nondiahetic (open circles, N = 170) patients on CAPD.
procedure. Radionuclide scans are not useful because of the
diffuse chronic inflammation in the peritoneum.
DR. JOHN T. HARRINUTON: Is the pH effect on peritoneal
phagocytosis reversible? If you incubate phagocytic cells for 30
minutes at a pH of 5.5 and then incubate the same cells at a pH
of 7.4, do they work or do they remain inhibited?
DR. VA5: The effect appears reversible.
DR. FRANCIS TALLY (Jnfrctious Disease Division, NEMC):
At what pH is phagocytosis inhibited?
DR. VA5: Inhibition of phagocytosis starts at approximately
pH 6.8; above 7.2, phagocytosis returns to completely normal.
24 26 DR. LAZARUS: Recently I saw a patient who received a
cephalosporin intraperitoneally and developed a severe maculo-
papular drug reaction. What is your experience with drug
reactions produced via the peritoneum, and do you treat the
patients differently?
DR. VA5: Hypersensitivity reactions are not more frequent
with intraperitoneal administration in our experience. If a
patient is hypersensitive to ccphalosporins, we use vancomy-
cm. Certain drugs have a very high rate of side effects when
given intraperitoneally. Virtually all patients who receive am-
photericin B or miconazole complain of abdominal pain and
flushing. We have not seen anaphylactic shock from the intra-
peritoneal use of antibiotics.
DR. SUSAN Hou (Renal Service, NEMC): Other agents
besides glucose are being investigated for use in peritoneal
dialysate to solve the problem of the excess caloric load. Do
any of these agents produce a different pH?
DR. VA5: One group is investigating the use of amino acids as
osmotic agents [55], but amino-acid containing solutions are not
yet available commercially. Such solutions are also slightly
acidic. Another group uses polymers as osmotically active
agents [56]. I don't know the pH of polymer-containing
solutions.
DR. TALLY: Are the resistant fungal infections caused by
Candida, or are there other types?
DR. VAS: We did have one instance of Aspergillus, two
it
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Fig. 5. Risk of peritonins in 47 CAPD patients before (open circles) and
after (closed circles) titaninin adapters and monthly tubing change.
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Fusarium, one Mucor and one Trichosporon infection, but most
of the resistant fungal infections were caused by Candida.
Acknowledgment
Parts of this work were supported by a contract with the
National Institutes of Health (No. NO—1-AM8--2213).
Reprint requests to Dr. S. I. Vas, Microbiologist in Chief Toronto
Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada M5T
2S8
References
1. MANDELL GL, VEST KT: Killing of intraleukocytic Staphylococcus
aureus by Rifampin: In vitro and in viva studies. J 1nf'ct Dis
125:486—490, 1971
2. ARCHER GL. TENENBAUM MJ. HARW000 HB: Rifampin therapy
of Staphylococcus epidermidis. Use in infections from indwelling
artificial devices. JAMA 240:751—753. 1978
3. KAPRAL FA. GODWIN JR, DYE ES: Formation of intraperitoneal
abscesses by Staphylococcus aureus. Infect Immun 30:204—211,
1980
4. CI-IESNEY PJ, DAVIS JP, PURDY WK. WAND PJ. CHESNEY RW:
Clinical manifestations of toxic shock syndrome. JAMA 246:741-..
748, 1981
5. TACK KJ: Possible tampon associated toxic shock syndrome in
man. Lancet 2:1354, 1981
6. REINGOLD AL, DAN BB. SHANDS KN, BROOME CV: Toxic shock
syndrome not associated with menstruation. Lancet 1:1—14, 1982
7. BOEN ST: Review of the clinical use of peritoneal dialysis, in
Peritoneal Dialysis, edited by NOLPH KD, The Hague, Martinus
NijhoffPubl, 1981. pp. 1—20
8. TENCKHOFF H, SCFTECHTER H: A bacteriologically safe peritoneal
access device. Trans Am Soc Artif Intern Organs 14:181—186, 1968
9. Poo'vici- RP, MONCRIEF JW, NOLPH KD, GFIODS AJ, TWAR-
DOWSKI AJ. PYLE WK: Continuous ambulatory peritoneal dialysis.
Am Intern Med 88:449—456, 1978
10. Oopouos DG, ROBSON M, JZATT S. CLAYTON 5, DEVEBER
GA: A simple and safe technique for continuous ambulatory
peritoneal dialysis. Trans Am Soc Artif Intern Organs 24:484—487.
1978
11. GOLPEN TA, BENNETT WM, JONES SR: Peritonitis associated with
chronic peritoneal dialysis. Dialys Transpl 7:1173—1178. 1978
12. OREoPouLos DG: Continuous ambulatory peritoneal dialysis in
Canada. Can Med Assoc J 120:16—19. 1979
13. RuBIN J, ROGERS WA, TAYLOR HM, EVERETT D, PROWANT BE.
FRUTO LV, NOEPH KD: Peritonitis during continuous ambulatory
peritoneal dialysis. Am Intern Med 92:7—13, 1980
14. VAS SI, Low DE, OREOPOULOS DG: Peritonitis, in Peritoneal
Dialysis, edited by NOLPH KD, The Hague. Martinus NijhoffPubl,
1981. pp. 334—365
15. Editorial: Antibiotic lavage for peritonitis. Br Med J 22:691—692.
1979
16. STEPHEN M, LOEwENTHAL J: Continuing peritoneal lavage in high
risk peritonitis. Surgery 85:603—606. 1979
17. STEPHEN RL, KABLITZ C, KITABARA M, NELSON JA, DUFFY DP.
KOEFF Wi: Peritoneal dialysis: Peritonitis: Saline-iodine flush.
Dialys Transpl 8:584—65.5. 1979
18. OREOPOULOS DG, VAS S. KHANNA R: Treatment of peritonitis in
patients on CAPD, in CAPD Update, edited by MONCRILI- JW.
PorovicH RD. New York. Masson Publishing USA Inc., 1980
19. VAS St. OREopouLos DG: Microbiological diagnostic approach of
continuous ambulatory peritoneal dialysis patients, in Continuous
Ambulatory Peritoneal Dialysis, edited by LEGRAIN M, Amster-
dam, Excerpla Medica, 1980. pp. 245—247
20. VA5 SI, Low DE, LAYNE S. KHANNA R, DOMBROS N: Microbio
logical diagnostic approach to peritonitis in CAPD patients, in
Peritoneal Dialysis, edited by ATKINS RC, THOMAS NM, FARREI.L
PC, Edinburgh. Churchill Livingstone. 1981. pp. 264—271
21. HAN T, AHRENHOLZ OH. SIMMONS RL: Secondary bacteria]
peritonitis: The biologic basis of treatment. Curr Prohl Surg 16:1—-
65, 1979
22. HAN T, PAYBE WD, SIMMONS RL: Fibrinolytic activity of the
peritoneum during experimental peritonitis. Surg Gynecol Obstet
148:415—418, 1979
23. MONTGOMERY JZ, KALMANSON GR, GUZE LB: Renal failure and
infection. Medicine 47:1—32, 1968
24. ABRUTYN E, SOLOMONS NW, ST CLAIR L, MACGREGOR RR, ROOT
RK: Granulocyte function in patients with chronic renal failure:
surface adherence, phagocytosis and bactericidal activity in vitro.
JlnfectDis 135:1—8, 1977
25. URBANITZ D, SIEBARTH HG: Impaired phagocytic activity of
human monocytes in respect to reduced antibacterial resistance in
uremia. Clin Nephrol 4:13—17, 1975
26. SELROOZ 0, PASTERNACK A, VIROLAIN M: Skin test Sensitivity and
antigen induced lymphocyte transformation in uremia. Clin Exp
Immunol 14:365—370, 1973
27. SENGAL DPS, RASHID A, HARRIS JE: In vitro cellular immunity
and in vivo delayed hypersensitivity in uremic patients maintained
on hemodialysis. Jut Arch Allergy AppI Im,nunol 47:829—838, 1974
28. DRIVAS G, RETHYMMIOTAKIS N, KALOS A, KALIAKMANIS N,
MELISSIN05 K: Reticuloendothelial phagocytosis in patients with
chronic renal failure. Invest Urol 17:241—243, 1979
29. SIRIWATRATANANONTA P, SIUSAKUL V, STERN K, SLAVIN RG:
Defective chemotaxis in uremia. J Lab Clin Med 92:402—407, 1978
30. VAS SI, DUWE A, WEATHERHEAD J: Natural defense mechanisms
of the peritoneum: The effect of peritoneal dialysis fluid on poly-
morphonuclear cells, in Peritoneal Dialysis, edited by ATKINS RC,
THOMAS NM, FARRELL PC, Edinburgh. Churchill Livingstone,
1981, pp. 41—51
31. DUWE AK, VAS SI, WEATHERHEAD JW: Effect of the composition
of peritoneal dialysis fluid on chemiluminescence, phagocytosis
and bactericidal activity in vitro. Infect I,nmun 33:130—135, 1981
32. O'LEARY JP, MALIK FS, DONOHUE RR, JOHNSTON AD: The effect
ofa mini dose of heparin on peritonitis in rats. Surg Gvnecol Obstet
148:571—575, 1979
33. ATKINS RC, HUMPHREY T. THOMSON N, WILLIAMSON J, HOOKE
D, DAVIDSON A: Bacterial and "sterile" peritonitis, in Peritoneal
Dialysis, edited by ATKINS RC, THOMAS NM, FARRELL PC,
Edinburgh, Churchill Livingstone, 1981, pp. 272—283
34. OREopoui,oS DG, KHANNA K, VAS SI: Peritonitis in patients on
CAPD, in Advances in Peritoneal Dialysis, edited by GAHL GM,
KESSEL M, NOLPH KD, Amsterdam. Excerpta Medica. 1981. pp.
26 1—264
35. WILLIAMS P, KHANNA R, VAS S. LAYNE 5, PANTALONY D,
OREOPOULOS DG: The treatment of peritonitis in patients on
CAPD: To lavage or not. Periton Dialys Bull 1:14—17, 1980
36. DIGENIS GE, KHANNA R. PIERATOS A, VAS 5: Morbidity and
mortality after treatment of peritonitis with prolonged exchanges
and intraperitoneal antibiotics. Periton Diulys Bull 2:45—46. 1982
37. WILLIAMS P, KHANNA R, SIMPSON H, VAS SI: Tobramycin blood
levels of CAPD patients during peritonitis. Periton Diulvs Bull 2:48,
1982
38. SMITH CR, LIPSKY ii, LASKIN OL, HELLMANN DB, MELLITS ED,
LONGSTRETH J, LEITMAN PS: Double-blind comparison of the
nephrotoxicity and auditory toxicity of gentamicin and tobramycin.
N Engl J Med 302:, 1106—1109, 1980
39. WILLIAMS F, PANTALONY D, VAS SI. KHANNA R, OREOPOULOS
DG: The value of clialysate cell count in the diagnosis of peritonitis
patients on continuous ambulatory peritoneal dialysis. Periton
Dialys Bull 1:59—62, 1981
40. KHANNA R, FENTON SS, CATTRAN DC, THOMSON D, DEITEL M,
OREOPOULOS DG: Tuberculous peritonitis in patients undergoing
continuous ambulatory peritoneal dialysis. Fenton Dialys Bull
1:10—12, 1981
41. O'CONNOR J, MACCORMIC M: Tuberculous peritonitis in patients
on CAPD. The importance of lymphocytosis in the peritoneal fluid.
Peniton Dialys Bull 1:106, 1981
42. KHANNA R, MCNEELY Di. OREopouLos DU, VAS SI. MCCREADY
W: Treating fungal infections; Fungal peritonitis in CAPD. Br Mcdi
280:1174—1148, 198(1
43. ARFANIA D, EVESETT ED, NOLPH KI), RUBIN J: Uncommon
causes of peritonitis in patients on peritoneal dialysis. Arch Intern
Med 141:61—64, 1981
44. ERMIN J, MARSHALL VC: The place of prophylactic antibiotic in
92 Nephrology Forum
peritoneal dialysis. Ausir Ann Med 18:264—266, 1969
45. SHARMA BK, SMITH EC, RODRIQUEZ H, PILLARY UKG, GANDHI
YC, DUNEA G: Trial of oral neomycin during peritoneal dialysis,
Am J Med Sci 262:175—178, 1971
46. AXEEROD J, MEYERS BR, HIRSCIIMAN SZ, STEIN R: l'rophylaxis
with cephalothin in peritoneal dialysis. Arch Intern Med 132:368—
371, 1973
47. Low DE, VAS SI, OREoPouLos DG, MANUEL RA, SAIPHOO CS,
FINER C, DOMBROS N: Randomized clinical trial of prophylactic
cephalexin in CAPD. Lancet 2:753—754, 1980
48. VAS SI, Low DE, ORFopoulos DO, MANUEL MA, SAIPH00 CS,
FINER C, DOMBROS N: Antibiotic prophylaxis in CAPD patients, in
PeritonealDialysis, edited by ATKINS RC, THOMAS NM, FARRELL
PC, Edinburgh, Churchill Livingstone, 1981, pp. 320—325
49. D'APICE AJF, ATKINS RC: Analysis of diarrhea data, in Peritoneal
Dialysis, edited by ATKINS RC, THOMAS NM, FARRELL PC,
Edinburgh, Churchill Livingstone, 1981, pp. 440—444
50. RANDERSON DH, FARRELL PC: Analysis of peritonitis data in
CAPD (abstract). 2nd International Symposium on Peritoneal
Dialysis, Berlin, 1981, p. 52
51. COREY P: An approach to the statistical analysis of peritonitis data
from patients on CAPD. Perilon Dialys Bull 1:529—532, 1981
52. PIERRATOS A, AMAIR P, COREY P, VAS SI, KHANNA R, ORr.oPou-
LOS DO: Statistical analysis of the incidence of peritonitis on
continuous ambulatory peritoneal dialysis. Periton Dialys Bull,
2:32—36, 1982
53. AMAIR P, KIIANNA R, LEIBEL B, PIERRATOS A, VAS S, MEEMA F,
BLAIR G, CHISHOLM L, VAS M, ZINGG W, DIGENIS G, OREoPoU-
LOS D: Continuous ambulatory peritoneal dialysis in diabetics with
end stage renal disease. N Engl J Med 306:625—630, 1982
54. Ci: Renal transplantation in patients on peritoneal
dialysis. Periton Dialys Bull 1:12—14, 1981
55. OREOPOUIOS DG, CRASSWF.LLF.R P, KATIRZOGLOU A, 0011 VIE R,
ZELLERMAN G, RODELLA H, VAS SI: Amino acids as an osmotic
agent, in CAPD in Continuous Ambulatoty Peritoneal Dialysis,
edited by LEGRAIN M, Amsterdam, Excerpta Medica, 1980, pp.
335—340
56. NOLPH KD, HOPKINS CA, RUBIN J: Polymer induced ultrafiltration
in dialysis: High osmotic pressure due to impermeant polymer
sodium. Trans Am Soc Arof Intern Organs 24:162—168, 1978
